Investigational drug · Phase 2
VP-16
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Recurrent Glioblastoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 22, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1,941
Any phase or sponsor naming "VP-16"
First trial start
2025
Aug 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VP-16", any sponsor or status.
Conditions studied
As listed on its trial records.
- Recurrent Glioblastoma
Approved drugs for the same conditions: Brain tumors (glioma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "VP-16" as an intervention, largest first.
- International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
University Hospital Schleswig-HolsteinAcademic, hospital or other
NCT01117441 · 6,136 participants · Start Jun 2010 · Primary completion Dec 31, 2021
Drug: PEG-L-asparaginase; cyclophosphamide and 14 more · For: Leukemia
Sites: Randwick, Australia; Westmead, Australia; Dornbirn, Austria · 139 sites in all
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive MutationsPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT02883049 · 5,949 participants · Start Feb 29, 2012 · Primary completion Dec 31, 2022
Drug: Clofarabine; Cyclophosphamide and 14 more · For: B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, BCR-ABL1-Like; Central Nervous System Leukemia and 1 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 239 sites in all
- Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017Pivotal-lookingRecruiting
Martin SchrappeAcademic, hospital or other
NCT03643276 · 5,000 participants (planned) · Start Jul 15, 2018 · Primary completion Jul 14, 2028
Drug: Blinatumomab; Bortezomib and 17 more · For: Acute Lymphoblastic Leukemia, Pediatric
Sites: Sydney, Australia; Westmead, Australia; Graz, Austria · 115 sites in all
- Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
University Hospital Schleswig-HolsteinAcademic, hospital or other
NCT00430118 · 4,559 participants · Start Jul 2000 · Primary completion Jan 2012
Drug: asparaginase; cyclophosphamide and 12 more · For: Leukemia
Sites: Dornbirn, Austria; Feldkirch-Tisis, Austria; Graz, Austria · 76 sites in all
- Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic LeukemiaPivotal-lookingStatus unknown
University Hospital, MotolAcademic, hospital or other
NCT00764907 · 4,000 participants (planned) · Start Nov 2002 · Primary completion Oct 2007
Drug: asparaginase; cyclophosphamide and 13 more · For: Leukemia
Sites: Prague, Czechia
- High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)Pivotal-lookingCompleted
St. Anna KinderkrebsforschungAcademic, hospital or other
NCT01704716 · 3,569 participants · Start Feb 1, 2002 · Primary completion Jan 30, 2025
Drug: Vincristine; Aldesleukin and 9 more · For: Neuroblastoma
Sites: Newcastle, Australia; Sydney, Australia; Vienna, Austria · 122 sites in all
Societe Internationale d'Oncologie PediatriqueAcademic, hospital or other
NCT00276640 · 3,417 participants · Start Apr 1, 2004 · Primary completion Dec 31, 2015
Drug: vincristine, carboplatin; vincristine, carboplatin, etoposide · For: Primary Central Nervous System Neoplasms
Sites: Vienna, Austria; Ghent, Belgium; Zagreb, Croatia · 13 sites in all
- Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung CancerPivotal-lookingCompleted
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
NCT00002823 · 3,300 participants (planned) · Start Feb 1995 · Primary completion Jan 2001
Drug: cisplatin; etoposide and 3 more · For: Lung Cancer
Sites: Atlantis, Florida; Boston, Massachusetts; Buenos Aires, Argentina · 123 sites in all
- Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney CancerPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00002611 · 3,031 participants · Start Jul 1995 · Primary completion Jun 2002
Drug: dactinomycin; filgrastim and 4 more · For: Kidney Cancer
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 235 sites in all
- Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and AdolescentsPivotal-lookingCompleted
University of GiessenAcademic, hospital or other
NCT02684708 · 2,921 participants · Start Oct 1, 2015 · Primary completion Oct 31, 2024
Drug: cyclophosphamide, vincristine, prednisone, dacarbazine; cyclo, vcr, pred, dacarb,etop and doxo · For: Classical Hodgkin Lymphoma
Sites: Victoria Park, Australia; Vienna, Austria; Leuven, Belgium · 19 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Retained Unexploded Ordnance: A Safety Analysis of Diagnostic Ultrasound on Piezoelectric Fuzes.
Kimball JD, Ogrydziak CE, Brill JB · Mil Med 2026
- Masquerade Syndrome Presenting as Optic Neuritis and Retinitis Due to Pituitary Germinoma.
Fukushima A, Kato Y, Tabuchi H · Cureus 2026
- Design, synthesis and biological evaluation of novel guanidine-containing matrine derivatives as Topo I/II dual target inhibitors.
Li S, Zhu Y, Wang Y, et al. · Eur J Med Chem 2026
- Multisystem Langerhans cell histiocytosis with hypothyroidism and sclerosing cholangitis: a case report and review of the literature.
Yu J, Liu X, Yu X, et al. · J Med Case Rep 2026
- Central venous catheter rupture following undiluted etoposide administration in a patient with multiple myeloma: A case report.
Lei T, Zhang L, Zhou J, et al. · J Vasc Access 2026
Also in development for Recurrent Glioblastoma
- KH617Phase 21 trial
Sichuan Honghe Biotechnology Co., Ltd. · Recurrent Glioblastoma
- TGX-007Phase 21 trial
Trogenix ltd · Glioblastoma (GBM), High Grade Gliomas, Recurrent Glioblastoma
- ValaciclovirPhase 21 trial
Trogenix ltd · Glioblastoma (GBM), High Grade Gliomas, Recurrent Glioblastoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.